H2020Обмен на изследователи2016–2020

EU4HIVCURE · Accelerating HIV Cure in Europe

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-02-01 → 2020-01-31
Финансиране от ЕС
310 500 €
Участници
7
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Нови комбинации от лекарства се тестват, за да „събудят“ скрития HIV вирус в клетките, за да стане той видим за имунната система. Това е важно, защото сегашните терапии не могат да премахнат тези резервоари от вируса в организма.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Accelerating HIV Cure in Europe

Finding a CURE for 37 Million individuals living with HIV/AIDS is one of the great global health challenges of the 21st century. The major obstacle to HIV eradication in patients under combination Anti-Retroviral therapy (cART) is the persistence of latent HIV cellular reservoirs, where the integrated viral genome is transcriptionally silenced but replication competent, and can escape both cART and immune response. Current strategies towards an HIV CURE aim at purging persistent latent reservoirs by forcing viral gene expression using epigenetic-modifying agents, including Histone Deacetylase inhibitors (HDACi) while maintaining patients on efficient cART. Once viral gene expression and viral particle production is reignited, the viral reservoirs are once again visible and can be targeted and eliminated by the immune system with the help of immune bosting strategies. However, in clinical trials, epigenetic inhibitors including SAHA, when used as single agents, have shown modest impact in inducing efficient HIV gene expression and/or virion production. Furthermore, there was no impact on the latent reservoir size in vivo. These studies highlight that additional layers of control for HIV gene silencing limit the impact of current LRA-based strategies and that these blocks need to be collectively unlocked if we want to effectively force HIV gene expression and viral production. To investigate novel avenues of research towards an HIV cure, it is critical to expand the repertoire of novel targetable proteins and to develop new classes of Latency Reversing Agents (LRAs) and combination of thereof, to be included as part new “Shock and Kill” strategies. In this context and driven by our common engagement in accelerating HIV CURE research in Europe, we have developed the EU4HIVCURE consortium, which is built upon dynamic collaborations between academic researchers and Infectious Diseases clinicians in Europe and was awarded the Horizon 2020 MSCA-RISE-2015 funding award from the European Commission.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Finding a CURE for 35 Million individuals living with HIV/AIDS is one of the great global health challenges of the 21st century. The major obstacle to HIV eradication is the persistence of latent HIV cellular reservoirs, where the integrated viral genome is transcriptionally silenced but replication-competent and can escape both Anti-Retroviral Therapy and Immune Responses. The development of novel strategies aimed at eliminating these reservoirs have become paramount in HIV research, if we want to achieve an HIV/AIDS CURE. To accelerate the State of the Art in HIV CURE research in Europe, our EU4HIVCURE consortium brings together an intersectoral and interdisciplinary collaboration between 3 Universities, 3 Hospitals, 1 International Research Organisation from 4 European countries and 1 University from Canada. Our aim is to dissect the intricate mechanisms controlling HIV-1 latency and identify new druggable targets to develop novel latency-reversing strategies and eradicate persistent viral reservoirs by forcing HIV-1 gene expression. To facilitate continuum for translation to the clinic, we have developed an operational framework, which maximises exchange of knowledge and expertise via secondements, networking and training activities.

Оригинален текст от CORDIS (на английски).

Участници

  • UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN · DublinКоординаторИрландия
  • ASSOCIATION HOSPITALIERE DE BRUXELLES-CENTRE HOSPITALIER UNIVERSITAIRE SAINT PIERRE · Bruxelles / BrusselБелгия
  • INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY · TriesteИталия
  • MATER MISERICORDIAE UNIVERSITY HOSPITAL · DublinИрландия
  • UNIVERSITE DE MONTREAL · MONTREALКанада
  • UNIVERSITE DE STRASBOURG · StrasbourgФранция
  • UNIVERSITE LIBRE DE BRUXELLES · Bruxelles / BrusselБелгия

Връзки

Данни: CORDIS, © Европейски съюз